1. Home
  2. KNDI vs BOLD Comparison

KNDI vs BOLD Comparison

Compare KNDI & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kandi Technologies Group Inc

KNDI

Kandi Technologies Group Inc

HOLD

Current Price

$0.72

Market Cap

69.7M

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$2.50

Market Cap

57.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
KNDI
BOLD
Founded
2002
2018
Country
China
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
69.7M
57.5M
IPO Year
2021
2024

Fundamental Metrics

Financial Performance
Metric
KNDI
BOLD
Price
$0.72
$2.50
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
470.0K
2.4M
Earning Date
04-28-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.47
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.57
$0.96
52 Week High
$1.77
$2.79

Technical Indicators

Market Signals
Indicator
KNDI
BOLD
Relative Strength Index (RSI) 50.16 68.09
Support Level $0.68 $2.35
Resistance Level $0.78 $2.79
Average True Range (ATR) 0.07 0.09
MACD 0.00 -0.03
Stochastic Oscillator 48.61 56.00

Price Performance

Historical Comparison
KNDI
BOLD

About KNDI Kandi Technologies Group Inc

Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: